Press Releases Year None2020201920182017 Turning Point Therapeutics Announces Pricing of $400 Million Public Offering of Common Stock Oct 26, 2020 Turning Point Therapeutics Announces Commencement of Public Offering of Common Stock Oct 26, 2020 Turning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR Symposium Oct 24, 2020 Turning Point Therapeutics to Host Conference Call to Discuss Presentations at 2020 EORTC-NCI-AACR Virtual Symposium Oct 22, 2020 Turning Point Therapeutics Announces Abstract For TRIDENT-1 Clinical Study of Repotrectinib Accepted For Presentation at World Conference on Lung Cancer Oct 21, 2020 Turning Point Therapeutics Announces Early Clinical Data For Novel MET Inhibitor TPX-0022 Selected For Late-Breaker Oral Presentation at 32nd EORTC-NCI-AACR Symposium Oct 07, 2020 Turning Point Therapeutics to Participate in Upcoming Virtual Investor Conference Sep 30, 2020 Turning Point Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference Sep 21, 2020 Turning Point Therapeutics to Participate in Upcoming Investor Conferences Sep 01, 2020 Turning Point Therapeutics Announces Scientific Advisory Board Aug 31, 2020 Pagination Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last » Displaying 1 - 10 of 34
Turning Point Therapeutics Announces Pricing of $400 Million Public Offering of Common Stock Oct 26, 2020
Turning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR Symposium Oct 24, 2020
Turning Point Therapeutics to Host Conference Call to Discuss Presentations at 2020 EORTC-NCI-AACR Virtual Symposium Oct 22, 2020
Turning Point Therapeutics Announces Abstract For TRIDENT-1 Clinical Study of Repotrectinib Accepted For Presentation at World Conference on Lung Cancer Oct 21, 2020
Turning Point Therapeutics Announces Early Clinical Data For Novel MET Inhibitor TPX-0022 Selected For Late-Breaker Oral Presentation at 32nd EORTC-NCI-AACR Symposium Oct 07, 2020
Turning Point Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference Sep 21, 2020
